This information was published on 2025-02-06T16:39:35 for IP Right Filed Published.
| Field | Value |
| (210) | 2519937 |
| (220) |
06 Feb 2025
|
| (300) |
US, 18 Jan 2025, 99012197
|
| (511) (510) |
Class 5
Gene therapy products, namely, genetically engineered tissues for transplant purposes; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; Gene therapy products, namely, rAAV vector for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases; Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant DNA for treating ocular diseases; Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa; Gene therapy products, namely, rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration. |
| (540) | SYTHEIA |
| (550) | Word |
| (730) |
Ocugen, Inc.
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.